Icatibant Medical Valley

Icatibant, the active ingredient in Icatibant Medical Valley, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats hereditary angioedema attacks in adults.

GNH USA supplies Icatibant Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway.

- Hereditary angioedema (HAE) attacks: provides rapid relief of swelling episodes in adult patients.

Adverse reactions may occur following subcutaneous administration of icatibant.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Redness or erythema: localized skin irritation. - Swelling at injection site: mild edema. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Worsening angioedema: paradoxical increase in swelling. - Severe hypotension: marked drop in blood pressure. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count observed in rare cases.

Prior to administration, clinicians should evaluate patient history and monitor for potential adverse events.

- Assess severity of HAE attack: confirm that the episode warrants icatibant therapy. - Monitor for hypersensitivity: watch for signs of allergic reaction during and after injection. - Avoid in known hypersensitivity: do not use in patients with documented icatibant allergy. - Use cautiously in cardiovascular disease: monitor blood pressure and heart rate. - Concomitant ACE inhibitor use: consider increased bradykinin risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin and heighten risk of angioedema. - Neprilysin inhibitors: can elevate bradykinin concentrations, potentially reducing icatibant efficacy.

Moderate Interactions (Monitor Closely): - Other B2 receptor antagonists: concurrent use may lead to additive effects. - Corticosteroids: may mask early signs of hypersensitivity. - Antihistamines: monitor for altered response to allergic reactions.